Does the media favor CMPX or VCEL?

In the previous week, Compass Therapeutics had 3 more articles in the media than Vericel. MarketBeat recorded 5 mentions for Compass Therapeutics and 2 mentions for Vericel. Vericel's average media sentiment score of 0.00 beat Compass Therapeutics' score of -0.08 indicating that Vericel is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Compass Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Vericel 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is PVLA or CMPX more profitable?

Compass Therapeutics' return on equity of -39.75% beat Palvella Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Palvella Therapeutics N/A -56.87% -42.50% Compass Therapeutics N/A -39.75% -35.29%

Does the media favor PVLA or CMPX?

In the previous week, Palvella Therapeutics had 2 more articles in the media than Compass Therapeutics. MarketBeat recorded 7 mentions for Palvella Therapeutics and 5 mentions for Compass Therapeutics. Palvella Therapeutics' average media sentiment score of 0.53 beat Compass Therapeutics' score of -0.08 indicating that Palvella Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Palvella Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Compass Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Is TSHA or CMPX more profitable?

Compass Therapeutics' return on equity of -39.75% beat Taysha Gene Therapies' return on equity. Company Net Margins Return on Equity Return on Assets Taysha Gene Therapies N/A -56.07% -40.16% Compass Therapeutics N/A -39.75% -35.29%

Does the media favor TSHA or CMPX?

In the previous week, Taysha Gene Therapies and Taysha Gene Therapies both had 5 articles in the media. Taysha Gene Therapies' average media sentiment score of 0.33 beat Compass Therapeutics' score of -0.08 indicating that Taysha Gene Therapies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Taysha Gene Therapies 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Compass Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer CMPX or ATAI?

In the previous week, Atai Beckley had 3 more articles in the media than Compass Therapeutics. MarketBeat recorded 8 mentions for Atai Beckley and 5 mentions for Compass Therapeutics. Atai Beckley's average media sentiment score of 1.04 beat Compass Therapeutics' score of -0.08 indicating that Atai Beckley is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Compass Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Atai Beckley 6 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CMPX or GLUE?

In the previous week, Compass Therapeutics had 3 more articles in the media than Monte Rosa Therapeutics. MarketBeat recorded 5 mentions for Compass Therapeutics and 2 mentions for Monte Rosa Therapeutics. Monte Rosa Therapeutics' average media sentiment score of 0.00 beat Compass Therapeutics' score of -0.08 indicating that Monte Rosa Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Compass Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Monte Rosa Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Compass Therapeutics (CMPX) Competitors

$2.02 -0.02 (-0.98%)

Closing price 04:00 PM Eastern

Extended Trading

$2.00 -0.02 (-0.74%)

As of 07:50 PM Eastern

Compare

CMPX vs. VCEL, PVLA, TSHA, ATAI, and GLUE

Should you buy Compass Therapeutics stock or one of its competitors? MarketBeat compares Compass Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Compass Therapeutics include Vericel (VCEL), Palvella Therapeutics (PVLA), Taysha Gene Therapies (TSHA), Atai Beckley (ATAI), and Monte Rosa Therapeutics (GLUE). These companies are all part of the "pharmaceutical products" industry.

How does Compass Therapeutics compare to Vericel?

Compass Therapeutics (NASDAQ:CMPX) and Vericel (NASDAQ:VCEL) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, media sentiment, risk, valuation, earnings and dividends.

Compass Therapeutics has a beta of 0.89, meaning that its stock price is 11% less volatile than the broader market. Comparatively, Vericel has a beta of 1.12, meaning that its stock price is 12% more volatile than the broader market.

Vericel has a net margin of 7.35% compared to Compass Therapeutics' net margin of 0.00%. Vericel's return on equity of 6.41% beat Compass Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compass Therapeutics	N/A	-39.75%	-35.29%
Vericel	7.35%	6.41%	4.61%

In the previous week, Compass Therapeutics had 3 more articles in the media than Vericel. MarketBeat recorded 5 mentions for Compass Therapeutics and 2 mentions for Vericel. Vericel's average media sentiment score of 0.00 beat Compass Therapeutics' score of -0.08 indicating that Vericel is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Compass Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Vericel	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Vericel has higher revenue and earnings than Compass Therapeutics. Compass Therapeutics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compass Therapeutics	$850K	427.98	-$66.49M	-$0.41	N/A
Vericel	$276.26M	6.61	$16.52M	$0.42	85.17

Compass Therapeutics currently has a consensus price target of $12.91, indicating a potential upside of 539.06%. Vericel has a consensus price target of $55.40, indicating a potential upside of 54.88%. Given Compass Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Compass Therapeutics is more favorable than Vericel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compass Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86
Vericel	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

68.4% of Compass Therapeutics shares are held by institutional investors. 18.7% of Compass Therapeutics shares are held by insiders. Comparatively, 7.6% of Vericel shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Vericel beats Compass Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Compass Therapeutics compare to Palvella Therapeutics?

Palvella Therapeutics (NASDAQ:PVLA) and Compass Therapeutics (NASDAQ:CMPX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability, institutional ownership and media sentiment.

In the previous week, Palvella Therapeutics had 2 more articles in the media than Compass Therapeutics. MarketBeat recorded 7 mentions for Palvella Therapeutics and 5 mentions for Compass Therapeutics. Palvella Therapeutics' average media sentiment score of 0.53 beat Compass Therapeutics' score of -0.08 indicating that Palvella Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Palvella Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Compass Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Compass Therapeutics' return on equity of -39.75% beat Palvella Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Palvella Therapeutics	N/A	-56.87%	-42.50%
Compass Therapeutics	N/A	-39.75%	-35.29%

40.1% of Palvella Therapeutics shares are owned by institutional investors. Comparatively, 68.4% of Compass Therapeutics shares are owned by institutional investors. 20.5% of Palvella Therapeutics shares are owned by company insiders. Comparatively, 18.7% of Compass Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Palvella Therapeutics has a beta of -0.14, suggesting that its stock price is 114% less volatile than the broader market. Comparatively, Compass Therapeutics has a beta of 0.89, suggesting that its stock price is 11% less volatile than the broader market.

Palvella Therapeutics currently has a consensus target price of $199.53, suggesting a potential upside of 89.58%. Compass Therapeutics has a consensus target price of $12.91, suggesting a potential upside of 539.06%. Given Compass Therapeutics' higher probable upside, analysts plainly believe Compass Therapeutics is more favorable than Palvella Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palvella Therapeutics	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.94
Compass Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

Palvella Therapeutics has higher revenue and earnings than Compass Therapeutics. Palvella Therapeutics is trading at a lower price-to-earnings ratio than Compass Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palvella Therapeutics	$42.81M	35.26	-$41.72M	-$4.17	N/A
Compass Therapeutics	$850K	427.98	-$66.49M	-$0.41	N/A

Summary

Compass Therapeutics beats Palvella Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Compass Therapeutics compare to Taysha Gene Therapies?

Taysha Gene Therapies (NASDAQ:TSHA) and Compass Therapeutics (NASDAQ:CMPX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, valuation, dividends, profitability, earnings, institutional ownership and risk.

77.7% of Taysha Gene Therapies shares are held by institutional investors. Comparatively, 68.4% of Compass Therapeutics shares are held by institutional investors. 3.8% of Taysha Gene Therapies shares are held by company insiders. Comparatively, 18.7% of Compass Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Taysha Gene Therapies and Taysha Gene Therapies both had 5 articles in the media. Taysha Gene Therapies' average media sentiment score of 0.33 beat Compass Therapeutics' score of -0.08 indicating that Taysha Gene Therapies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Taysha Gene Therapies	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Compass Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Taysha Gene Therapies has a beta of 1.19, meaning that its stock price is 19% more volatile than the broader market. Comparatively, Compass Therapeutics has a beta of 0.89, meaning that its stock price is 11% less volatile than the broader market.

Taysha Gene Therapies currently has a consensus price target of $11.64, suggesting a potential upside of 114.30%. Compass Therapeutics has a consensus price target of $12.91, suggesting a potential upside of 539.06%. Given Compass Therapeutics' higher possible upside, analysts plainly believe Compass Therapeutics is more favorable than Taysha Gene Therapies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Taysha Gene Therapies	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Compass Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

Compass Therapeutics' return on equity of -39.75% beat Taysha Gene Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Taysha Gene Therapies	N/A	-56.07%	-40.16%
Compass Therapeutics	N/A	-39.75%	-35.29%

Compass Therapeutics has lower revenue, but higher earnings than Taysha Gene Therapies. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Compass Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Taysha Gene Therapies	$9.77M	159.71	-$109M	-$0.38	N/A
Compass Therapeutics	$850K	427.98	-$66.49M	-$0.41	N/A

Summary

Compass Therapeutics beats Taysha Gene Therapies on 8 of the 15 factors compared between the two stocks.

How does Compass Therapeutics compare to Atai Beckley?

Compass Therapeutics (NASDAQ:CMPX) and Atai Beckley (NASDAQ:ATAI) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, profitability, dividends, risk and analyst recommendations.

In the previous week, Atai Beckley had 3 more articles in the media than Compass Therapeutics. MarketBeat recorded 8 mentions for Atai Beckley and 5 mentions for Compass Therapeutics. Atai Beckley's average media sentiment score of 1.04 beat Compass Therapeutics' score of -0.08 indicating that Atai Beckley is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Compass Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Atai Beckley	6 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Compass Therapeutics has a beta of 0.89, meaning that its share price is 11% less volatile than the broader market. Comparatively, Atai Beckley has a beta of 1.6, meaning that its share price is 60% more volatile than the broader market.

Compass Therapeutics has a net margin of 0.00% compared to Atai Beckley's net margin of -19,019.44%. Compass Therapeutics' return on equity of -39.75% beat Atai Beckley's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compass Therapeutics	N/A	-39.75%	-35.29%
Atai Beckley	-19,019.44%	-89.79%	-63.58%

Compass Therapeutics currently has a consensus price target of $12.91, indicating a potential upside of 539.06%. Atai Beckley has a consensus price target of $16.00, indicating a potential upside of 319.95%. Given Compass Therapeutics' higher possible upside, analysts plainly believe Compass Therapeutics is more favorable than Atai Beckley.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compass Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86
Atai Beckley	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91

Compass Therapeutics has higher earnings, but lower revenue than Atai Beckley. Compass Therapeutics is trading at a lower price-to-earnings ratio than Atai Beckley, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compass Therapeutics	$850K	427.98	-$66.49M	-$0.41	N/A
Atai Beckley	$4.09M	342.97	-$660.05M	-$2.23	N/A

68.4% of Compass Therapeutics shares are held by institutional investors. Comparatively, 28.4% of Atai Beckley shares are held by institutional investors. 18.7% of Compass Therapeutics shares are held by company insiders. Comparatively, 26.8% of Atai Beckley shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Compass Therapeutics beats Atai Beckley on 9 of the 17 factors compared between the two stocks.

How does Compass Therapeutics compare to Monte Rosa Therapeutics?

Compass Therapeutics (NASDAQ:CMPX) and Monte Rosa Therapeutics (NASDAQ:GLUE) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings.

Compass Therapeutics presently has a consensus target price of $12.91, suggesting a potential upside of 539.06%. Monte Rosa Therapeutics has a consensus target price of $32.50, suggesting a potential upside of 91.18%. Given Compass Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Compass Therapeutics is more favorable than Monte Rosa Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compass Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86
Monte Rosa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Compass Therapeutics has a net margin of 0.00% compared to Monte Rosa Therapeutics' net margin of -302.69%. Compass Therapeutics' return on equity of -39.75% beat Monte Rosa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compass Therapeutics	N/A	-39.75%	-35.29%
Monte Rosa Therapeutics	-302.69%	-40.99%	-25.94%

Monte Rosa Therapeutics has higher revenue and earnings than Compass Therapeutics. Monte Rosa Therapeutics is trading at a lower price-to-earnings ratio than Compass Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compass Therapeutics	$850K	427.98	-$66.49M	-$0.41	N/A
Monte Rosa Therapeutics	$123.67M	11.61	-$38.63M	-$1.48	N/A

Compass Therapeutics has a beta of 0.89, indicating that its share price is 11% less volatile than the broader market. Comparatively, Monte Rosa Therapeutics has a beta of 1.6, indicating that its share price is 60% more volatile than the broader market.

68.4% of Compass Therapeutics shares are owned by institutional investors. Comparatively, 80.0% of Monte Rosa Therapeutics shares are owned by institutional investors. 18.7% of Compass Therapeutics shares are owned by insiders. Comparatively, 6.4% of Monte Rosa Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Compass Therapeutics had 3 more articles in the media than Monte Rosa Therapeutics. MarketBeat recorded 5 mentions for Compass Therapeutics and 2 mentions for Monte Rosa Therapeutics. Monte Rosa Therapeutics' average media sentiment score of 0.00 beat Compass Therapeutics' score of -0.08 indicating that Monte Rosa Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Compass Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Monte Rosa Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Compass Therapeutics beats Monte Rosa Therapeutics on 11 of the 17 factors compared between the two stocks.

Get Compass Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CMPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CMPX vs. The Competition

Export

Metric	Compass Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$367.38M	$3.34B	$6.49B	$11.99B
Dividend Yield	N/A	2.30%	2.67%	5.58%
P/E Ratio	-4.93	18.61	23.92	23.74
Price / Sales	427.98	298.40	507.55	107.95
Price / Cash	N/A	51.45	26.99	37.25
Price / Book	1.82	8.04	10.28	6.78
Net Income	-$66.49M	$23.89M	$3.57B	$337.51M
7 Day Performance	-9.01%	-5.97%	-1.43%	-2.72%
1 Month Performance	10.38%	2.78%	3.27%	1.87%
1 Year Performance	-19.20%	36.26%	23.37%	26.60%

Compass Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CMPX Compass Therapeutics	2.3236 of 5 stars	$2.02 -1.0%	$12.91 +539.1%	-18.4%	$367.38M	$850K	N/A	20
VCEL Vericel	2.6317 of 5 stars	$32.82 -1.5%	$55.40 +68.8%	-16.2%	$1.70B	$276.26M	78.14	300	Analyst Upgrade
PVLA Palvella Therapeutics	2.9363 of 5 stars	$112.59 -5.0%	$199.53 +77.2%	+327.8%	$1.70B	$42.81M	N/A	N/A	Positive News
TSHA Taysha Gene Therapies	3.5305 of 5 stars	$5.97 +1.7%	$11.64 +94.9%	+93.7%	$1.69B	$9.77M	N/A	180
ATAI Atai Beckley	3.5669 of 5 stars	$4.82 +6.4%	$16.00 +232.0%	+63.9%	$1.67B	$4.09M	N/A	80	Positive News Analyst Forecast Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CMPX) was last updated on 6/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compass Therapeutics (CMPX) Competitors

CMPX vs. VCEL, PVLA, TSHA, ATAI, and GLUE

How does Compass Therapeutics compare to Vericel?

Summary

How does Compass Therapeutics compare to Palvella Therapeutics?

Summary

How does Compass Therapeutics compare to Taysha Gene Therapies?

Summary

How does Compass Therapeutics compare to Atai Beckley?

Summary

How does Compass Therapeutics compare to Monte Rosa Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMPX vs. The Competition

Compass Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compass Therapeutics (CMPX) Competitors

CMPX vs. VCEL, PVLA, TSHA, ATAI, and GLUE

How does Compass Therapeutics compare to Vericel?

Which has more risk and volatility, CMPX or VCEL?

Is CMPX or VCEL more profitable?

Does the media favor CMPX or VCEL?

Which has higher earnings & valuation, CMPX or VCEL?

Do analysts prefer CMPX or VCEL?

Do insiders & institutionals believe in CMPX or VCEL?

Summary

How does Compass Therapeutics compare to Palvella Therapeutics?

Does the media favor PVLA or CMPX?

Is PVLA or CMPX more profitable?

Do insiders and institutionals hold more shares of PVLA or CMPX?

Which has more volatility & risk, PVLA or CMPX?

Do analysts recommend PVLA or CMPX?

Which has better valuation and earnings, PVLA or CMPX?

Summary

How does Compass Therapeutics compare to Taysha Gene Therapies?

Do institutionals & insiders hold more shares of TSHA or CMPX?

Does the media favor TSHA or CMPX?

Which has more volatility and risk, TSHA or CMPX?

Do analysts rate TSHA or CMPX?

Is TSHA or CMPX more profitable?

Which has preferable earnings & valuation, TSHA or CMPX?

Summary

How does Compass Therapeutics compare to Atai Beckley?

Does the media prefer CMPX or ATAI?

Which has more risk and volatility, CMPX or ATAI?

Is CMPX or ATAI more profitable?

Do analysts prefer CMPX or ATAI?

Which has stronger earnings & valuation, CMPX or ATAI?

Do insiders & institutionals have more ownership in CMPX or ATAI?

Summary

How does Compass Therapeutics compare to Monte Rosa Therapeutics?

Do analysts recommend CMPX or GLUE?

Is CMPX or GLUE more profitable?

Which has higher valuation and earnings, CMPX or GLUE?

Which has more volatility and risk, CMPX or GLUE?

Do institutionals and insiders hold more shares of CMPX or GLUE?

Does the media prefer CMPX or GLUE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMPX vs. The Competition

Compass Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools